Erbitux (cetuximab) - Eli Lilly
Antigen-independent BCR signals limit differentiation and survival of IgM antibody-secreting cells. (PubMed, J Exp Med) - Oct 25, 2026 - "Leveraging this mechanistic insight, we demonstrated that SYK KO in engineered PCs (ePCs) significantly improved output and in vivo durability of IgM-cetuximab-secreting ePCs. Together, these findings reveal IgM-BCR signaling as a previously unrecognized negative regulator of human IgM PC differentiation and survival and show that inhibition of BCR-proximal pathways can improve IgM-based cellular immunotherapies." 
Journal • IRF4 • PRDM1 • SYK
http://www.ncbi.nlm.nih.gov/pubmed/42911265
 
Ameena Romani; Brock McKinney; David J Rawlings; Gregory D Asher; Nathan Camp; Parker Knebusch; Richard G James; Ting-Ting Zhang; Yu Chen
 
Oct 25, 2026
 
Prev Next